{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060553","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.471372+00:00","generated_at":"2026-06-01T23:29:45.834236+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"HCW Biologics Q1 net loss widens to $7.5M; going concern doubt persists","bullets":["Net loss of $7.5M vs $5.1M in Q1 2023; revenue rose to $1.1M from $41,883 due to Wugen sales.","G&A expenses surged 94% to $6.0M driven by legal costs for Altor/NantCell arbitration hearing set for May 20.","Completed Phase 1/1b trials for HCW9218 in solid tumors; RP2D established; plans ovarian cancer Phase 2 with UPMC in H2 2024.","Raised $6.1M YTD; bridge financing target $10M in secured notes ($3.6M issued); going concern uncertainty remains.","IND for HCW9302 in autoimmune disease planned for Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060553","json":"https://secwatch.observer/filing/0000950170-24-060553.json","markdown":"https://secwatch.observer/filing/0000950170-24-060553.md","text":"https://secwatch.observer/filing/0000950170-24-060553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000095017024060553/0000950170-24-060553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000095017024060553/hcwb-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:29:45.834236+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7bfaaa1f6bb744f88ac6bd048f618147c763ca6a","claim":"HCW Biologics Inc. reported first quarter ended March 31, 2024 results: revenue $1.1 million, net income $7.5 million.","evidence_excerpt":"we plan to submit in the third quarter of 2024. 2 First Quarter 2024 Financial Results • Revenues: Revenues for the first quarters ended March 31, 2023 and 2024 were $41,883 and $1.1 million, respectively. Revenues in both periods were derived exclusively from the sale of licensed molecules to the Company’s licensee, Wugen. The licensed molecules are one of the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828673/000095017024060553/0000950170-24-060553-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$1.1 million"},{"label":"Net income","value":"$7.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}